mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-5-89-95mrj-1204Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОпыт применения гуселькумаба в лечении больных псориатическим артритом в реальной клинической практикеExperience of guselkumab usage in the treatment of patients with psoriatic arthritis in real clinical practicehttps://orcid.org/0000-0001-6875-4552ЛогиноваЕ. Ю.LoginovaE. Yu.

Елена Юрьевна Логинова

115522, Москва, Каширское шоссе, 34А

Elena Yurievna Loginova

34A, Kashirskoe Shosse, Moscow 115522

eyloginova@mail.ruhttps://orcid.org/0000-0001-5968-2403КорсаковаЮ. Л.KorsakovaYu. L.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2021191020211558995Copyright © Логинова Е.Ю., Корсакова Ю.Л., Коротаева Т.В., 20212021Логинова Е.Ю., Корсакова Ю.Л., Коротаева Т.В.Loginova E.Y., Korsakova Y.L., Korotaeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1204

В статье представлен анализ данных литературы об эффективности и безопасности применения нового генно-инженерного биологического препарата ингибитора интерлейкина 23 – гуселькумаба (ГУС) – в лечении пациентов с псориатическим артритом (ПсА). Описаны два собственных клинических наблюдения, в которых проводилась терапия ГУС. Продемонстрировано, что при ПсА умеренной активности и тяжелом и среднетяжелом псориазе с поражением ногтей применение ГУС в дозе 100 мг на неделях 0 и 4, а затем каждые 8 нед позволяет достичь ремиссии периферического артрита, энтезита и псориаза к 20-й неделе лечения как в режиме монотерапии, так и в комбинации с метотрексатом. При повторном назначении ГУС (re-treat) после длительного перерыва (10 мес) быстро и полностью восстанавливается его эффективность. Подтверждена безопасность ГУС у пациентов с коморбидной патологией, в частности с синдромом Жильбера, гиперурикемией, метаболическими нарушениями (абдоминальным ожирением).

The article presents an analysis of literature on the efficacy and safety of a new biologic disease modifying antirheumatic drug usage, the interleukin 23 inhibitor – guselkumab (GUS) – in the treatment of patients with psoriatic arthritis (PsA). Two own clinical observations of GUS therapy are described. It has been demonstrated that in PsA of moderate activity and in severe to moderate psoriasis with nail damage, the use of GUS (100 mg at weeks 0 and 4, and then every 8 weeks), allows to achieve remission of peripheral arthritis, enthesitis and psoriasis by the 20th week of treatment as in the monotherapy regimen and in combination with methotrexate. When GUS is re-prescribed (re-treat) after a long break (10 months), its effectiveness is quickly and completely restored. The safety of GUS was confirmed in patients with comorbid pathology, in particular, Gilbert's syndrome, hyperuricemia, metabolic disorders (abdominal obesity).

псориатический артритпсориазгуселькумабгенно-инженерные биологические препаратыpsoriatic arthritispsoriasisguselkumabbiologic disease modifying antirheumatic drugsИсследование выполнено в рамках научной темы «Патогенетические особенности и персонифицированная терапия анкилозирующего спондилита и псориатического артрита» (АААА-А19-119021190147-6, 0514-2019-0009).The investigation has been conducted within scientific topic №АААА-А19-119021190147-6, 0514-2019-0009 «Pathogenetic features and personalized therapy of ankylosing spondylitis and psoriatic arthritis».ReferencesGladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii14-7. doi: 10.1136/ard.2004.032482.Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii14-7. doi: 10.1136/ard.2004.032482.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.Brahe CH, Ornbjerg LM, Jacobsson L, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EUROSPA. Rheumatology (Oxford). 2020 Jul 1;59(7): 1640-50. doi: 10.1093/rheumatology/kez427.Brahe CH, Ornbjerg LM, Jacobsson L, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EUROSPA. Rheumatology (Oxford). 2020 Jul 1;59(7): 1640-50. doi: 10.1093/rheumatology/kez427.Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147-57. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 Sep;80(9):1147-57. doi: 10.1136/annrheumdis-2020-219014. Epub 2021 May 13.Noviani M, Feletar M, Nash P, Leung Y. Choosing the right treatment for patientswith psoriatic arthritis. Ther Adv Musculoskelet Dis. 2020 Oct 13;12:1759720X20962623. doi: 10.1177/1759720X20962623.eCollection 2020.Noviani M, Feletar M, Nash P, Leung Y. Choosing the right treatment for patientswith psoriatic arthritis. Ther Adv Musculoskelet Dis. 2020 Oct 13;12:1759720X20962623. doi: 10.1177/1759720X20962623.eCollection 2020.Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. Apr-May 2014;13(4-5):496-502. doi: 10.1016/j.autrev.2014.01.050. Epub 2014 Jan 11.Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. Apr-May 2014;13(4-5):496-502. doi: 10.1016/j.autrev.2014.01.050. Epub 2014 Jan 11.Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1616-26. doi: 10.1111/jdv.14433. Epub 2017 Aug 29.Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1616-26. doi: 10.1111/jdv.14433. Epub 2017 Aug 29.McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167-78. doi: 10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5.McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167-78. doi: 10.1136/annrheumdis-2019-215356. Epub 2019 Jul 5.Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018 Aug 2;9:1682. doi: 10.3389/fimmu.2018.01682. eCollection 2018.Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018 Aug 2;9:1682. doi: 10.3389/fimmu.2018.01682. eCollection 2018.Raychaudhuri S, Raychaudhuri S. Regulatory role of IL-23 and its receptor system in spondyloarthritis and its therapeutic relevance in anti-IL-17 failure patients. Arthritis Rheumatol. 2019;71(suppl 10):1014.Raychaudhuri S, Raychaudhuri S. Regulatory role of IL-23 and its receptor system in spondyloarthritis and its therapeutic relevance in anti-IL-17 failure patients. Arthritis Rheumatol. 2019;71(suppl 10):1014.Kulig P, Musiol S, Freiberger SN, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016 Nov 28;7:13466. doi: 10.1038/ncomms13466.Kulig P, Musiol S, Freiberger SN, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016 Nov 28;7:13466. doi: 10.1038/ncomms13466.Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013 May;65(5):1213-23. doi: 10.1002/art.37876.Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013 May;65(5):1213-23. doi: 10.1002/art.37876.Haddad A, Gazitt I, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021 Jan 29;23(1):44. doi: 10.1186/s13075-021-02417-x.Haddad A, Gazitt I, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021 Jan 29;23(1):44. doi: 10.1186/s13075-021-02417-x.Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. Arthritis Care Res (Hoboken). 2021 Jan 18. doi: 10.1002/acr.24560. Online ahead of print.Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. Arthritis Care Res (Hoboken). 2021 Jan 18. doi: 10.1002/acr.24560. Online ahead of print.Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with selfreported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treatedwithbiologics. BMC Rheumatol. 2019 Nov 28;3:52. doi: 10.1186/s41927-019-0094-3. eCollection 2019.Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with selfreported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treatedwithbiologics. BMC Rheumatol. 2019 Nov 28;3:52. doi: 10.1186/s41927-019-0094-3. eCollection 2019.Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2.Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2.Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018 Jun 2;391(10136): 2213-24. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018 Jun 2;391(10136): 2213-24. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.Deodhar A, Helliwell P, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115-25. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13.Deodhar A, Helliwell P, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115-25. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13.Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4; 395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13.Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4; 395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13.Coates L, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who demonstrated inadequate response to tumor necrosis factor inhibition: Week 24 results of a phase 3b, randomized, controlled study. Ann Rheum Dis. 2021;80(Suppl 1):141.Coates L, Gossec L, Theander E, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who demonstrated inadequate response to tumor necrosis factor inhibition: Week 24 results of a phase 3b, randomized, controlled study. Ann Rheum Dis. 2021;80(Suppl 1):141.Reich K, Griffiths ChEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr;82(4): 936-45. doi: 10.1016/j.jaad.2019.11.040.Epub 2019 Dec 4.Reich K, Griffiths ChEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr;82(4): 936-45. doi: 10.1016/j.jaad.2019.11.040.Epub 2019 Dec 4.Gordon KB, Armstrong AW, Foley P, et al. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019 Dec;139(12):2437-46.e1. doi: 10.1016/j.jid.2019.05.016. Epub 2019 Jun 15.Gordon KB, Armstrong AW, Foley P, et al. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019 Dec;139(12):2437-46.e1. doi: 10.1016/j.jid.2019.05.016. Epub 2019 Jun 15.McInnes I, Rahman P, Gottlieb A, et al. Efficacy and safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal antibody, through one year in biological-naїve patients with psoriatic arthritis. Arthritis Rheumatol. 2021 Apr;73(4):604-16. doi: 10.1002/art.41553. Epub 2021 Mar 17.McInnes I, Rahman P, Gottlieb A, et al. Efficacy and safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal antibody, through one year in biological-naїve patients with psoriatic arthritis. Arthritis Rheumatol. 2021 Apr;73(4):604-16. doi: 10.1002/art.41553. Epub 2021 Mar 17.Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021 May 14;60(5): 2109-21. doi: 10.1093/rheumatology/keab119.Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021 May 14;60(5): 2109-21. doi: 10.1093/rheumatology/keab119.

The authors declare that there are no conflicts of interest present.